Knight Therapeutics Announces Health Canada Approval for WYNZORA(R) to Treat Psoriasis Vulgaris
Knight Therapeutics Announces Health Canada Approval for WYNZORA(R) to Treat Psoriasis Vulgaris GlobeNewswire December 18, 2025 MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA(R), a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 […]